Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 9/20 | 0.69 |
| ▸ | GAA | P10253 | 9/20 | 0.69 |
| ▸ | SI | P14410 | 9/20 | 0.69 |
| ▸ | MGAM2 | Q2M2H8 | 9/20 | 0.69 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.67 |
| ▸ | PARP1 | P09874 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | HPGD | P15428 | 3/20 | 0.66 |
| ▸ | NPC1 | O15118 | 2/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | DHODH | Q02127 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7040235 | 0.86 | MGAM (0.52) | MGAMGAASIMGAM2HPSE | |
| SCHEMBL6585826 | 0.85 | HPSE (0.67) | MGAMGAASIMGAM2HPSE | |
| SCHEMBL7943515 | 0.84 | PARP1 (0.69) | MGAMGAASIMGAM2PARP1 | |
| SCHEMBL30615069 | 0.83 | MGAM (0.76) | MGAMGAASIMGAM2HPSE | |
| SCHEMBL5074029 | 0.83 | MGAM (0.76) | MGAMGAASIMGAM2HPSE | |
| SCHEMBL13133302 | 0.82 | MGAM (1.00) | MGAMGAASIMGAM2HPSE | |
| SCHEMBL6056826 | 0.82 | MGAM (0.77) | MGAMGAASIMGAM2HPSE | |
| SCHEMBL6265383 | 0.81 | HPSE (0.76) | MGAMGAASIMGAM2HPSE | |
| SCHEMBL29790551 | 0.81 | PARP1 (1.00) | PARP1DHODH | |
| SCHEMBL6529350 | 0.81 | HPSE (1.00) | MGAMGAASIMGAM2HPSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010024833-A1 | Methods for the solid phase synthesis of combinatorial libraries of benzimidazol, benzoxazoles, benzothiazoles, and derivatives thereof | LABORDE EDGARDO (US) | 2001-09-27 | — | — | US | claimed |
| US-6251689-B1 | BINDING TO RESIN; OXIDATION | TELIK, INC. | 2001-06-26 | — | — | US | claimed |
| US-20010024833-A1 | Methods for the solid phase synthesis of combinatorial libraries of benzimidazol, benzoxazoles, benzothiazoles, and derivatives thereof | LABORDE EDGARDO (US) | 2001-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010024833-A1 | Methods for the solid phase synthesis of combinatorial libraries of benzimidazol, benzoxazoles, benzothiazoles, and derivatives thereof | EIF2AK2, CDK15, CDK17 | MGAM 3387/4885GAA 2677/4885SI 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.